Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Gets UK Early Access OK For New Hemophilia Drug

Executive Summary

The UK regulator is allowing patients to be treated with Roche’s as yet unlicensed hemophilia drug, emicizumab, under the country’s early access scheme. Hemlibra is already approved in the US and is in the final stages of review in the EU, where it is undergoing accelerated assessment.

Advertisement

Related Content

Seven Green Lights From EU’s CHMP, Including Drugs For Hemophilia, Diabetes, Alpha Mannosidosis And Hyperkalemia
Roche’s Hemlibra Looking For CHMP Green Light, Crunch Time for Santhera DMD Hopeful
‘Outstanding Issues’ Near For Products Approaching EU Review End – Including Neulasta Biosimilar
Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern

Topics

Advertisement
UsernamePublicRestriction

Register

PS122241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel